Answers are grounded in this paper and cite their sources.
Meta-analysis shows neoadjuvant immune checkpoint inhibitors improve outcomes in localized gastric cancer, suggesting longer treatment durations may enhance effectiveness.
Neoadjuvant ICIs are associated with favorable efficacy and safety in localized dMMR/MSI-H gastric and GEJ cancers. Longer neoadjuvant exposure (≥3 months) may improve pCR rates. Larger prospective studies are needed to define optimal treatment duration and the role of organ-preserving strategies such as NOM.
No takes yet. Share an insight, caveat, or question.
Schwengber et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: